Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 121 results for "Mk 5172"

Summary from CROI 2015 for Hepatitis C HIV/HCV coinfected pati...

At this year CROI, viral hepatitis once again, represents one of the major topics with new data from phase-3 clinical studies in coinfection, as well as feedback from implementation of DAA-based therapy in real-life HIV/HCV cohorts being presented. National AIDS Treatment Advocacy Project, 4 days ago

Merck & Co. (MRK) Can't Catch a Break for Sugammadex, Faces Third FDA Rejection 3/17/2015

March 16, 2015 By Mark Terry , BioSpace.com Breaking News Staff Kenilworth, N.J.-based Merck & Co. ( MRK ) announced Friday that the U.S. Food and Drug Administration (FDA) had canceled its March 18 meeting of the Anesthetic and Analgesic Drug ...
 ClinicSpace1 week ago Merck & Co. (MRK) to Stop Selling Once-Hot Hep C Drug Victrelis 1/23/2015  ClinicSpace2 months ago
Orthopedics Today

Two HCV Treatments Lose Breakthrough Therapy Designation

According to two manufacturers, the FDA is taking the new landscape of hepatitis C virus treatments into consideration and removing the designation of breakthrough therapy for two different regimens. The FDA has rescinded breakthrough therapy ...
 Orthopedics Today1 week ago MERCK & CO., INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.  Pharmacy Choice4 weeks ago Bristol-Myers Squibb Company (BMY)'s Hepatitis C Drug to Lose Special Breakthrough Status From the FDA 2/11/2015  ClinicSpace1 month ago Merck Posts Disappointing Numbers As Experimental Hepatitis C Treatment Loses Breakthrough Designation  Trefis1 month ago
[x]  

These Two Catalysts Can Move Merck's Stock Up

Despite the recent pressure on revenues resulting from loss of patent exclusivity for some drugs and adverse currency movements, Merck (NYSE:MRK) continues t0 streamline its research and development expenses and execute in key growth markets. The ...
 Trefis2 weeks ago
Gizmodo

Hunting a Silent Killer: How to Cure Hepatitis C in the Undiagnosed

Hepatitis C has a cure, but how do we find those who need it? Patrick Strudwick reports on one attempt to identify some of the estimated 100,000 undiagnosed people in the UK. A young woman jeans and boots and wild hair is sitting in a cubicle ...
 Gizmodo1 month ago
Motley Fool

In Case You Missed It, There's a New Fastest Growing Drug in the World

Ladies and gentlemen, for the third time in less than four years we've witnessed the fastest growing drug in the world get unseated. A walk down memory lane As a refresher, in May 2011, the Food and Drug Administration approved a revolutionary new ...
 Motley Fool1 month ago
Motley Fool

1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep

Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big pharmaceutical companies, ...
 Motley Fool1 month ago
Citybizlist

Merck & Co., Inc. Earnings: 1 Sentence That Changed Everything

Put plainly, Wall Street and investors aren't too happy with pharmaceutical giant Merck (NYSE: MRK Merck's top-line takes a beating For the quarter, Merck watched as its total revenue slumped 7% to $10.48 billion from $11.32 billion in Q4 2013.
 Motley Fool1 month ago

FDA to retract breakthrough therapy designation of grazoprevir/elbasvir combo for HCV

The FDA plans to retract breakthrough therapy designation status for the combination regimen of grazoprevir and elbasvir to treat chronic hepatitis C virus infection, according to 2014 financial results released by Merck. According to the ...
 Orthopedics Today1 month ago Breakthroughs Aren't Forever  Corante1 month ago

Financial Highlights Package

By Business Wire | 02/04/15 - 07:02 AM EST Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2014. Fourth Quarter Year Ended ...
 TheStreet.com1 month ago Merck Announces Fourth-Quarter and Full-Year 2014 Financial Results  CNBC1 month ago Merck : Announces Fourth-Quarter and Full-Year 2014 Financial Results  4 Traders1 month ago Merck & Co drops marketing of hepatitis C drug Victrelis in USA  Pharma Letter2 months ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less